GlassScriptPhysician profile
Scott L Osur
NPI 1831190636
$10,923.73
in general payments reported to CMS, 2019-2025
14 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,869 · 2020: $3,600 · 2021: $137 · 2022: $123 · 2023: $438 · 2024: $563 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177 · Education: $17.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,177.12 |
| Education | $17.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $9,193.71 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals LP | $562.00 | 2021-2024 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $260.31 | 2019-2024 | Xolair |
| Merck Sharp & Dohme LLC | $151.56 | 2019-2023 | |
| Ars Pharmaceuticals Operations, INC. | $124.94 | 2025 | Neffy |
| Shire North American Group INC | $124.06 | 2019 | |
| Incyte Corporation | $122.88 | 2022 | |
| Optinose US, INC. | $103.61 | 2019 | |
| Blueprint Medicines Corporation | $68.37 | 2024 | |
| Amgen INC. | $60.26 | 2024-2025 | Tezspire |
| Csl Behring | $56.87 | 2023-2024 | Haegarda, Kcentra |
| Novartis Pharmaceuticals Corporation | $51.81 | 2021-2024 | |
| Kaleo, INC. | $30.47 | 2021 | |
| Pfizer INC. | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Osur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.